{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T15:42:46Z","timestamp":1787240566176,"version":"build-2736575974"},"reference-count":201,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Blood Reviews"],"published-print":{"date-parts":[[2024,1]]},"DOI":"10.1016\/j.blre.2023.101140","type":"journal-article","created":{"date-parts":[[2023,10,27]],"date-time":"2023-10-27T22:05:25Z","timestamp":1698444325000},"page":"101140","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":12,"special_numbering":"C","title":["A paradox of choice: Sequencing therapy in relapsed\/refractory diffuse large B-cell lymphoma"],"prefix":"10.1016","volume":"63","author":[{"given":"Taylor R.","family":"Brooks","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paolo F.","family":"Caimi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.blre.2023.101140_bb0005","first-page":"66(6)","article-title":"US lymphoid malignancy statistics by World Health Organization subtypes","volume":"2016","author":"Teras","year":"2016","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.blre.2023.101140_bb0010","series-title":"SEER Cancer Stat Facts: Non-Hodgkin lymphoma","author":"National Cancer Institute","year":"2023"},{"issue":"12","key":"10.1016\/j.blre.2023.101140_bb0015","doi-asserted-by":"crossref","DOI":"10.1182\/blood-2010-03-276246","article-title":"Long-term outcome of patients in the LNH-98.5 trial, the first randomized study comparing rituximab-CHOP to standard CHOP chemotherapy in DLBCL patients: a study by the Groupe d\u2019Etudes des Lymphomes de l\u2019Adulte","volume":"116","author":"Coiffier","year":"2010","journal-title":"Blood."},{"key":"10.1016\/j.blre.2023.101140_bb0020","article-title":"Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin\u2019s lymphoma","volume":"333","author":"Thierry Philip","year":"1995","journal-title":"N Engl J Med"},{"key":"10.1016\/j.blre.2023.101140_bb0025","article-title":"Outcomes of autologous hematopoietic cell transplantation in diffuse large B cell lymphoma refractory to Firstline Chemoimmunotherapy","author":"Bal","year":"2020","journal-title":"Biol Blood Marrow Transplant"},{"issue":"4","key":"10.1016\/j.blre.2023.101140_bb0030","doi-asserted-by":"crossref","DOI":"10.2217\/fon-2020-0522","article-title":"Real-world practice patterns and outcomes in veterans with relapsed\/refractory diffuse large B-cell lymphoma","volume":"17","author":"Chien","year":"2021","journal-title":"Future Oncol"},{"issue":"2","key":"10.1016\/j.blre.2023.101140_bb0035","doi-asserted-by":"crossref","DOI":"10.1002\/ajh.24615","article-title":"Diffuse large B-cell lymphoma with primary treatment failure: ultra-high risk features and benchmarking for experimental therapies","volume":"92","author":"Costa","year":"2017","journal-title":"Am J Hematol"},{"issue":"1","key":"10.1016\/j.blre.2023.101140_bb0040","doi-asserted-by":"crossref","DOI":"10.1111\/bjh.14813","article-title":"Clinical heterogeneity of diffuse large B cell lymphoma following failure of front-line immunochemotherapy","volume":"179","author":"Farooq","year":"2017","journal-title":"Br J Haematol"},{"issue":"27","key":"10.1016\/j.blre.2023.101140_bb0045","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2010.28.1618","article-title":"Salvage regimens with autologous transplantation for relapsed large B-cell lymphoma in the rituximab era","volume":"28","author":"Gisselbrecht","year":"2010","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.blre.2023.101140_bb0050","article-title":"Real-world management and outcomes of patients with relapsed\/refractory diffuse large B-cell lymphoma treated in the United States","volume":"6","author":"Klink","year":"2020","journal-title":"J Clincal Pathw"},{"issue":"4","key":"10.1016\/j.blre.2023.101140_bb0055","doi-asserted-by":"crossref","DOI":"10.1016\/j.clml.2020.11.008","article-title":"Outcomes of transplant-eligible patients with relapsed or refractory diffuse large B-cell lymphoma after second-line salvage chemotherapy: the Gustave Roussy experience","volume":"21","author":"Rassy","year":"2021","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"31","key":"10.1016\/j.blre.2023.101140_bb0060","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2013.53.9593","article-title":"Randomized comparison of gemcitabine, dexamethasone, and cisplatin versus dexamethasone, cytarabine, and cisplatin chemotherapy before autologous stem-cell transplantation for relapsed and refractory aggressive lymphomas: NCIC-CTG LY.12","volume":"32","author":"Crump","year":"2014","journal-title":"J Clin Oncol"},{"issue":"9","key":"10.1016\/j.blre.2023.101140_bb0065","article-title":"Progression-free survival at 24 months as a landmark after autologous stem cell transplant in relapsed or refractory diffuse large B-cell lymphoma","volume":"28","author":"Tun","year":"2022","journal-title":"Transplant Cell Ther"},{"issue":"16","key":"10.1016\/j.blre.2023.101140_bb0070","doi-asserted-by":"crossref","DOI":"10.1182\/blood-2017-03-769620","article-title":"Outcomes in refractory diffuse large B-cell lymphoma: results from the international SCHOLAR-1 study","volume":"130","author":"Crump","year":"2017","journal-title":"Blood."},{"issue":"21","key":"10.1016\/j.blre.2023.101140_bb0075","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V124.21.3069.3069","article-title":"Outcome in unselected patients with relapsed\/refractory diffuse large B-cell lymphoma (DLBCL) following R-CHOP when stem cell transplantation is not feasible","volume":"124","author":"Kansara","year":"2014","journal-title":"Blood."},{"issue":"7","key":"10.1016\/j.blre.2023.101140_bb0080","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa2116596","article-title":"Second-line Tisagenlecleucel or standard Care in Aggressive B-cell lymphoma","volume":"386","author":"Bishop","year":"2022","journal-title":"N Engl J Med"},{"issue":"10343","key":"10.1016\/j.blre.2023.101140_bb0085","doi-asserted-by":"crossref","DOI":"10.1016\/S0140-6736(22)00662-6","volume":"399","author":"Kamdar","year":"2022","journal-title":"Lancet"},{"issue":"7","key":"10.1016\/j.blre.2023.101140_bb0090","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa2116133","article-title":"Axicabtagene Ciloleucel as second-line therapy for large B-cell lymphoma","volume":"386","author":"Locke","year":"2022","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.blre.2023.101140_bb0095","doi-asserted-by":"crossref","DOI":"10.1046\/j.1365-2141.2001.03181.x","article-title":"An oxaliplatin-based chemotherapy in patients with relapsed or refractory intermediate and high-grade non-Hodgkin\u2019s lymphoma","volume":"115","author":"Chau","year":"2001","journal-title":"Br J Haematol"},{"issue":"8","key":"10.1016\/j.blre.2023.101140_bb0100","doi-asserted-by":"crossref","DOI":"10.3109\/10428194.2010.491137","article-title":"Efficacy and safety of gemcitabine, carboplatin, dexamethasone, and rituximab in patients with relapsed\/refractory lymphoma: a prospective multi-center phase II study by the Puget Sound oncology consortium","volume":"51","author":"Gopal","year":"2010","journal-title":"Leuk Lymphoma"},{"issue":"4","key":"10.1016\/j.blre.2023.101140_bb0105","doi-asserted-by":"crossref","DOI":"10.3816\/CLML.2010.n.055","article-title":"Rituximab, dexamethasone, cytarabine, and oxaliplatin (R-DHAX) is an effective and safe salvage regimen in relapsed\/refractory B-cell non-hodgkin lymphoma","volume":"10","author":"Lignon","year":"2010","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"6","key":"10.1016\/j.blre.2023.101140_bb0110","doi-asserted-by":"crossref","DOI":"10.1007\/s00277-017-2981-2","article-title":"Carboplatin instead of cisplatin in combination with dexamethasone, high-dose cytarabine with or without rituximab (DHAC+\/\u2212R) is an effective treatment with low toxicity in Hodgkin\u2019s and non-Hodgkin\u2019s lymphomas","volume":"96","author":"Tessoulin","year":"2017","journal-title":"Ann Hematol"},{"issue":"4","key":"10.1016\/j.blre.2023.101140_bb0115","doi-asserted-by":"crossref","DOI":"10.1007\/s00277-006-0243-9","article-title":"Rituximab plus ASHAP for the treatment of patients with relapsed or refractory aggressive non-Hodgkin\u2019s lymphoma: a single-centre study of 20 patients","volume":"86","author":"Aydin","year":"2007","journal-title":"Ann Hematol"},{"issue":"1","key":"10.1016\/j.blre.2023.101140_bb0120","doi-asserted-by":"crossref","DOI":"10.1080\/10428194.2016.1187274","article-title":"Effect of the addition of rituximab to salvage chemotherapy prior to autologous stem cell transplant in aggressive CD20+ lymphoma: a cohort comparison from the NCIC clinical trials group study LY.12*","volume":"58","author":"Baetz","year":"2017","journal-title":"Leuk Lymphoma"},{"issue":"6","key":"10.1016\/j.blre.2023.101140_bb0125","article-title":"Rituximab in combination with platinum-containing chemotherapy in patients with relapsed or primary refractory diffuse large B-cell lymphoma","volume":"10","author":"Bieker","year":"2003","journal-title":"Oncol Rep"},{"issue":"11","key":"10.1016\/j.blre.2023.101140_bb0130","doi-asserted-by":"crossref","DOI":"10.1016\/j.bbmt.2009.07.017","article-title":"Impact of pre-transplant rituximab on survival after autologous hematopoietic stem cell transplantation for diffuse large B cell lymphoma","volume":"15","author":"Fenske","year":"2009","journal-title":"Biol Blood Marrow Transplant"},{"issue":"12","key":"10.1016\/j.blre.2023.101140_bb0135","doi-asserted-by":"crossref","DOI":"10.1093\/annonc\/mdx556","article-title":"Refractory or relapsed aggressive B-cell lymphoma failing (R)-CHOP: an analysis of patients treated on the RICOVER-60 trial","volume":"28","author":"Glass","year":"2017","journal-title":"Ann Oncol"},{"key":"10.1016\/j.blre.2023.101140_bb0140","article-title":"The combination of ifosfamide, carboplatin, and etoposide \u00b1 rituximab is a safe and effective salvage therapy for elderly patients with diffuse large b-cell lymphoma","volume":"33","author":"Herishanu","year":"2015","journal-title":"Hematol Oncol"},{"issue":"11","key":"10.1016\/j.blre.2023.101140_bb0145","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V108.11.3067.3067","article-title":"Rituximab increases response to ESHAP in relapsed, refractory, and transformed aggressive B-cell lymphoma","volume":"108","author":"Hicks","year":"2006","journal-title":"Blood."},{"issue":"10","key":"10.1016\/j.blre.2023.101140_bb0150","doi-asserted-by":"crossref","first-page":"3684","DOI":"10.1182\/blood-2003-11-3911","article-title":"Rituximab and ICE as second-line therapy before autologous stem cell transplantation for relapsed or primary refractory diffuse large B-cell lymphoma","volume":"103","author":"Kewalramani","year":"2004","journal-title":"Blood."},{"issue":"12","key":"10.1016\/j.blre.2023.101140_bb0155","doi-asserted-by":"crossref","DOI":"10.3324\/haematol.13440","article-title":"R-ESHAP as salvage therapy for patients with relapsed or refractory diffuse large B-cell lymphoma: the influence of prior exposure to rituximab on outcome. A GEL\/TAMO study","volume":"93","author":"Mart\u00edn","year":"2008","journal-title":"Haematologica."},{"issue":"6","key":"10.1016\/j.blre.2023.101140_bb0160","doi-asserted-by":"crossref","DOI":"10.1080\/07357900600814490","article-title":"Dexamethasone, high-dose cytarabine, and cisplatin in combination with rituximab as salvage treatment for patients with relapsed or refractory aggressive non-Hodgkin\u2019s lymphoma","volume":"24","author":"Mey","year":"2006","journal-title":"Cancer Invest"},{"issue":"19","key":"10.1016\/j.blre.2023.101140_bb0165","doi-asserted-by":"crossref","DOI":"10.1002\/cncr.25216","article-title":"Oxaliplatin-based chemotherapy (dexamethasone, high-dose cytarabine, and oxaliplatin) \u00b1 rituximab is an effective salvage regimen in patients with relapsed or refractory lymphoma","volume":"116","author":"Rigacci","year":"2010","journal-title":"Cancer."},{"issue":"2","key":"10.1016\/j.blre.2023.101140_bb0170","doi-asserted-by":"crossref","DOI":"10.1007\/s00277-006-0210-5","article-title":"Rituximab added to an intensified salvage chemotherapy program followed by autologous stem cell transplantation improved the outcome in relapsed and refractory aggressive non-Hodgkin lymphoma","volume":"86","author":"Sieniawski","year":"2007","journal-title":"Ann Hematol"},{"issue":"Suppl. 1","key":"10.1016\/j.blre.2023.101140_bb0175","article-title":"Outpatient regimen rituximab plus ifosfamide, carboplatin and etoposide (R-ICE) for relapsed non-Hodgkin\u2019s lymphoma","volume":"14","author":"Vose","year":"2003","journal-title":"Ann Oncol"},{"issue":"2","key":"10.1016\/j.blre.2023.101140_bb0180","doi-asserted-by":"crossref","DOI":"10.1182\/blood-2007-08-108415","article-title":"Rituximab improves the treatment results of DHAP-VIM-DHAP and ASCT in relapsed\/progressive aggressive CD20+ NHL: a prospective randomized HOVON trial","volume":"111","author":"Vellenga","year":"2008","journal-title":"Blood."},{"issue":"5","key":"10.1016\/j.blre.2023.101140_bb0185","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2016.69.0198","article-title":"Ofatumumab versus rituximab salvage chemoimmunotherapy in relapsed or refractory diffuse large B-cell lymphoma: the ORCHARRD study","volume":"35","author":"Van Imhoff","year":"2017","journal-title":"J Clin Oncol"},{"issue":"23","key":"10.1016\/j.blre.2023.101140_bb0190","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2012.46.9585","article-title":"Obinutuzumab (GA101) monotherapy in relapsed\/refractory diffuse large b-cell lymphoma or mantle-cell lymphoma: results from the phase II GAUGUIN study","volume":"31","author":"Morschhauser","year":"2013","journal-title":"J Clin Oncol"},{"issue":"5","key":"10.1016\/j.blre.2023.101140_bb0195","doi-asserted-by":"crossref","DOI":"10.1016\/j.bbmt.2011.10.010","article-title":"High-dose therapy and autologous stem cell transplantation in first relapse for diffuse large B cell lymphoma in the rituximab era: an analysis based on data from the European blood and marrow transplantation registry","volume":"18","author":"Mounier","year":"2012","journal-title":"Biol Blood Marrow Transplant"},{"issue":"10","key":"10.1016\/j.blre.2023.101140_bb0200","doi-asserted-by":"crossref","DOI":"10.1158\/1078-0432.CCR-17-3561","article-title":"Updated results of rituximab pre- and post-beam with or without90Yttrium ibritumomab tiuxetan during autologous transplant for diffuse large b-cell lymphoma","volume":"24","author":"Chahoud","year":"2018","journal-title":"Clin Cancer Res"},{"issue":"36","key":"10.1016\/j.blre.2023.101140_bb0205","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2012.41.9416","article-title":"Rituximab maintenance therapy after autologous stem-cell transplantation in patients with relapsed CD20+ diffuse large B-cell lymphoma: final analysis of the collaborative trial in relapsed aggressive lymphoma","volume":"30","author":"Gisselbrecht","year":"2012","journal-title":"J Clin Oncol"},{"issue":"3","key":"10.1016\/j.blre.2023.101140_bb0210","doi-asserted-by":"crossref","DOI":"10.1182\/blood-2003-04-1257","article-title":"Rituximab as adjuvant to high-dose therapy and autologous hematopoietic cell transplantation for aggressive non-Hodgkin lymphoma","volume":"103","author":"Horwitz","year":"2004","journal-title":"Blood."},{"issue":"10","key":"10.1016\/j.blre.2023.101140_bb0215","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2005.08.012","article-title":"Concurrent administration of high-dose rituximab before and after autologous stem-cell transplantation for relapsed aggressive B-cell non-Hodgkin\u2019s lymphomas","volume":"23","author":"Khouri","year":"2005","journal-title":"J Clin Oncol"},{"issue":"4","key":"10.1016\/j.blre.2023.101140_bb0220","doi-asserted-by":"crossref","DOI":"10.1111\/bjh.14731","article-title":"A randomized phase II study of standard-dose versus high-dose rituximab with BEAM in autologous stem cell transplantation for relapsed aggressive B-cell non-hodgkin lymphomas: long term results","volume":"178","author":"Srour","year":"2017","journal-title":"Br J Haematol"},{"issue":"19","key":"10.1016\/j.blre.2023.101140_bb0225","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2007.14.4204","article-title":"Rituximab improves the efficacy of high-dose chemotherapy with autograft for high-risk follicular and diffuse large B-cell lymphoma: a multicenter Gruppo Italiano Terapie Innnovative nei Linfomi survey","volume":"26","author":"Tarella","year":"2008","journal-title":"J Clin Oncol"},{"issue":"13","key":"10.1016\/j.blre.2023.101140_bb0230","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2012.45.9453","volume":"31","author":"Vose","year":"2013","journal-title":"J Clin Oncol"},{"issue":"10","key":"10.1016\/j.blre.2023.101140_bb0235","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.1998.16.10.3264","article-title":"Time to relapse has prognostic value in patients with aggressive lymphoma enrolled onto the Parma trial","volume":"16","author":"Guglielmi","year":"1998","journal-title":"J Clin Oncol"},{"issue":"11","key":"10.1016\/j.blre.2023.101140_bb0240","doi-asserted-by":"crossref","first-page":"1839","DOI":"10.1007\/s00277-015-2467-z","article-title":"Outcome of patients with primary refractory diffuse large B cell lymphoma after R-CHOP treatment","volume":"94","author":"Hitz","year":"2015","journal-title":"Ann Hematol"},{"issue":"23","key":"10.1016\/j.blre.2023.101140_bb0245","doi-asserted-by":"crossref","first-page":"2683","DOI":"10.1182\/blood.V126.23.2683.2683","article-title":"Treatment patterns and outcomes of DLBCL after failure of front-line Immunochemotherapy","volume":"126","author":"Farooq","year":"2015","journal-title":"Blood."},{"key":"10.1016\/j.blre.2023.101140_bb0250","doi-asserted-by":"crossref","first-page":"2524","DOI":"10.1182\/blood-2021-146206","article-title":"Time to refractory status defines subsets of primary refractory diffuse large B-cell lymphoma with distinct outcomes","volume":"138","author":"Bock","year":"2021","journal-title":"Blood."},{"issue":"S2","key":"10.1016\/j.blre.2023.101140_bb0255","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1002\/hon.3164_317","article-title":"Defining primary refractory diffuse large B-cell lymphoma (DLBCL) based on survival outcomes","volume":"41","author":"Bock","year":"2023","journal-title":"Hematol Oncol"},{"issue":"Supplement 1","key":"10.1016\/j.blre.2023.101140_bb0260","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1182\/blood-2022-170752","article-title":"Outcomes of DLBCL patients achieving complete remission after R-ICE Chemoimmunotherapy","volume":"140","author":"Caimi","year":"2022","journal-title":"Blood."},{"issue":"20","key":"10.1016\/j.blre.2023.101140_bb0265","doi-asserted-by":"crossref","first-page":"4619","DOI":"10.1182\/blood-2012-01-406033","article-title":"MYC+ diffuse large B-cell lymphoma is not salvaged by classical R-ICE or R-DHAP followed by BEAM plus autologous stem cell transplantation","volume":"119","author":"Cuccuini","year":"2012","journal-title":"Blood."},{"issue":"1","key":"10.1016\/j.blre.2023.101140_bb0270","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1200\/JCO.2016.68.2740","article-title":"Relapsed or refractory double-expressor and double-hit lymphomas have inferior progression-free survival after autologous stem-cell transplantation","volume":"35","author":"Herrera","year":"2017","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"issue":"2","key":"10.1016\/j.blre.2023.101140_bb0275","doi-asserted-by":"crossref","first-page":"288","DOI":"10.3324\/haematol.2017.179309","article-title":"A bioclinical prognostic model using MYC and BCL2 predicts outcome in relapsed\/refractory diffuse large B-cell lymphoma","volume":"103","author":"Bosch","year":"2018","journal-title":"Haematologica."},{"issue":"15","key":"10.1016\/j.blre.2023.101140_bb0280","doi-asserted-by":"crossref","first-page":"5101","DOI":"10.1002\/cam4.4062","article-title":"Clinicopathological analysis of primary refractory diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisolone chemoimmunotherapy","volume":"10","author":"Suzuki","year":"2021","journal-title":"Cancer Med"},{"issue":"31","key":"10.1016\/j.blre.2023.101140_bb0285","doi-asserted-by":"crossref","first-page":"4079","DOI":"10.1200\/JCO.2011.35.4423","article-title":"The germinal center\/activated B-cell subclassification has a prognostic impact for response to salvage therapy in relapsed\/refractory diffuse large B-cell lymphoma: a bio-CORAL study","volume":"29","author":"Thieblemont","year":"2011","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"issue":"11","key":"10.1016\/j.blre.2023.101140_bb0290","doi-asserted-by":"crossref","first-page":"2017","DOI":"10.1007\/s00259-014-2822-7","article-title":"Pretherapy metabolic tumour volume is an independent predictor of outcome in patients with diffuse large B-cell lymphoma","volume":"41","author":"Sasanelli","year":"2014","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"2","key":"10.1016\/j.blre.2023.101140_bb0295","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1182\/blood-2018-01-826958","article-title":"Metabolic heterogeneity on baseline 18FDG-PET\/CT scan is a predictor of outcome in primary mediastinal B-cell lymphoma","volume":"132","author":"Ceriani","year":"2018","journal-title":"Blood."},{"issue":"8","key":"10.1016\/j.blre.2023.101140_bb0300","doi-asserted-by":"crossref","first-page":"1965","DOI":"10.1080\/10428194.2018.1562181","article-title":"PET-derived tumor metrics predict DLBCL response and progression-free survival","volume":"60","author":"Islam","year":"2019","journal-title":"Leuk Lymphoma"},{"issue":"24","key":"10.1016\/j.blre.2023.101140_bb0305","doi-asserted-by":"crossref","first-page":"3679","DOI":"10.1182\/blood-2015-03-635169","article-title":"Noninvasive monitoring of diffuse large B-cell lymphoma by immunoglobulin high-throughput sequencing","volume":"125","author":"Kurtz","year":"2015","journal-title":"Blood."},{"issue":"5","key":"10.1016\/j.blre.2023.101140_bb0310","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1016\/S1470-2045(15)70106-3","article-title":"Circulating tumour DNA and CT monitoring in patients with untreated diffuse large B-cell lymphoma: a correlative biomarker study","volume":"16","author":"Roschewski","year":"2015","journal-title":"Lancet Oncol"},{"issue":"5","key":"10.1016\/j.blre.2023.101140_bb0315","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.20.01751","article-title":"Autologous stem cell transplantation in the Management of Relapsed non-Hodgkin Lymphoma","volume":"39","author":"Alencar","year":"2021","journal-title":"J Clin Oncol"},{"issue":"9","key":"10.1016\/j.blre.2023.101140_bb0320","doi-asserted-by":"crossref","DOI":"10.2217\/fon-2018-0788","article-title":"Evaluation of treatment patterns and survival among patients with diffuse large B-cell lymphoma in the USA","volume":"15","author":"Morrison","year":"2019","journal-title":"Future Oncol"},{"issue":"7","key":"10.1016\/j.blre.2023.101140_bb0325","doi-asserted-by":"crossref","DOI":"10.1080\/10428194.2020.1734592","article-title":"The economic burden to payers of patients with diffuse large B-cell lymphoma during the treatment period by line of therapy","volume":"61","author":"Tkacz","year":"2020","journal-title":"Leuk Lymphoma"},{"issue":"5","key":"10.1016\/j.blre.2023.101140_bb0330","doi-asserted-by":"crossref","DOI":"10.1111\/bjh.12176","article-title":"Prognostic factors for patients with diffuse large B cell lymphoma and transformed indolent lymphoma undergoing autologous stem cell transplantation in the positron emission tomography era","volume":"160","author":"Armand","year":"2013","journal-title":"Br J Haematol"},{"issue":"9","key":"10.1016\/j.blre.2023.101140_bb0335","doi-asserted-by":"crossref","DOI":"10.1002\/cncr.23861","article-title":"Pretransplantation positron emission tomography scan is the main predictor of autologous stem cell transplantation outcome in aggressive B-cell non-Hodgkin lymphoma","volume":"113","author":"Derenzini","year":"2008","journal-title":"Cancer."},{"issue":"1","key":"10.1016\/j.blre.2023.101140_bb0340","doi-asserted-by":"crossref","DOI":"10.1111\/j.1365-2141.2010.08162.x","article-title":"Improved survival for relapsed diffuse large B cell lymphoma is predicted by a negative pre-transplant FDG-PET scan following salvage chemotherapy: research paper","volume":"150","author":"Dickinson","year":"2010","journal-title":"Br J Haematol"},{"issue":"12","key":"10.1016\/j.blre.2023.101140_bb0345","doi-asserted-by":"crossref","DOI":"10.1038\/bmt.2008.408","article-title":"The role of FDG-PET imaging and involved field radiotherapy in relapsed or refractory diffuse large B-cell lymphoma","volume":"43","author":"Hoppe","year":"2009","journal-title":"Bone Marrow Transplant"},{"issue":"16","key":"10.1016\/j.blre.2023.101140_bb0350","doi-asserted-by":"crossref","DOI":"10.1182\/blood-2014-10-606939","article-title":"Prognostic value of FDG-PET prior to autologous stem cell transplantation for relapsed and refractory diffuse large B-cell lymphoma","volume":"125","author":"Sauter","year":"2015","journal-title":"Blood."},{"issue":"1","key":"10.1016\/j.blre.2023.101140_bb0355","doi-asserted-by":"crossref","DOI":"10.1182\/blood-2002-12-3842","article-title":"Prognostic value of pretransplantation positron emission tomography using fluorine 18-fluorodeoxyglucose in patients with aggressive lymphoma treated with high-dose chemotherapy and stem cell transplantation","volume":"102","author":"Spaepen","year":"2003","journal-title":"Blood."},{"issue":"11","key":"10.1016\/j.blre.2023.101140_bb0360","doi-asserted-by":"crossref","DOI":"10.1182\/bloodadvances.2019000102","article-title":"Postrelapse survival in diffuse large B-cell lymphoma after therapy failure following autologous transplantation","volume":"3","author":"Epperla","year":"2019","journal-title":"Blood Adv"},{"issue":"6","key":"10.1016\/j.blre.2023.101140_bb0365","doi-asserted-by":"crossref","DOI":"10.6004\/jnccn.2019.0029","article-title":"NCCN guidelines insights: B-cell lymphomas, version 3.2019","volume":"17","author":"Zelenetz","year":"2019","journal-title":"J Natl Compr Canc Netw"},{"issue":"11","key":"10.1016\/j.blre.2023.101140_bb0370","article-title":"CAR T-cell therapy in large B-cell lymphoma","volume":"378","author":"SS N, FL L, WY G","year":"2018","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.blre.2023.101140_bb0375","doi-asserted-by":"crossref","DOI":"10.1016\/S1470-2045(18)30864-7","article-title":"Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1\u20132 trial","volume":"20","author":"Locke","year":"2019","journal-title":"Lancet Oncol"},{"issue":"Supplement 1","key":"10.1016\/j.blre.2023.101140_bb0380","first-page":"40","article-title":"Long-term survival and gradual recovery of B cells in patients with refractory large B cell lymphoma treated with Axicabtagene Ciloleucel (Axi-Cel)","volume":"136","author":"Jacobson","year":"2020","journal-title":"Blood."},{"issue":"Supplement 1","key":"10.1016\/j.blre.2023.101140_bb0385","doi-asserted-by":"crossref","DOI":"10.1182\/blood-2021-148078","article-title":"Long-term (\u22654 year and \u22655 year) overall survival (OS) by 12- and 24-month event-free survival (EFS): an updated analysis of ZUMA-1, the pivotal study of axicabtagene ciloleucel (Axi-Cel) in patients (pts) with refractory large B-cell lymphoma (LBCL)","volume":"138","author":"Jacobson","year":"2021","journal-title":"Blood."},{"key":"10.1016\/j.blre.2023.101140_bb0390","series-title":"Abstr 2022 Tandem Meet ASTCT CIBMTR","first-page":"S9","article-title":"10 - Long-Term (5 Year) Overall Survival in Zuma-1, the Pivotal Study of Axicabtagene Ciloleucel (Axi-Cel) in Patients with Refractory Large B-Cell Lymphoma (LBCL)","volume":"28","author":"Jacobson","year":"2022"},{"issue":"27","key":"10.1016\/j.blre.2023.101140_bb0395","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.19.02103","article-title":"Axicabtagene ciloleucel in the non-trial setting: outcomes and correlates of response, resistance, and toxicity","volume":"38","author":"Jacobson","year":"2020","journal-title":"J Clin Oncol"},{"issue":"27","key":"10.1016\/j.blre.2023.101140_bb0400","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.19.02104","article-title":"Standard-of-care axicabtagene ciloleucel for relapsed or refractory large B-cell lymphoma: results from the US lymphoma CAR T consortium","volume":"38","author":"Nastoupil","year":"2020","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.blre.2023.101140_bb0405","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa1804980","article-title":"Tisagenlecleucel in adult relapsed or refractory diffuse large B-cell lymphoma","volume":"380","author":"Schuster","year":"2019","journal-title":"N Engl J Med"},{"issue":"10","key":"10.1016\/j.blre.2023.101140_bb0410","doi-asserted-by":"crossref","DOI":"10.1016\/S1470-2045(21)00375-2","article-title":"Long-term clinical outcomes of tisagenlecleucel in patients with relapsed or refractory aggressive B-cell lymphomas (JULIET): a multicentre, open-label, single-arm, phase 2 study","volume":"22","author":"Schuster","year":"2021","journal-title":"Lancet Oncol"},{"issue":"10254","key":"10.1016\/j.blre.2023.101140_bb0415","doi-asserted-by":"crossref","DOI":"10.1016\/S0140-6736(20)31366-0","article-title":"Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study","volume":"396","author":"Abramson","year":"2020","journal-title":"Lancet"},{"issue":"Supplement 1","key":"10.1016\/j.blre.2023.101140_bb0420","doi-asserted-by":"crossref","DOI":"10.1182\/blood-2021-148948","article-title":"Two-year follow-up of Transcend NHL 001, a Multicenter phase 1 study of Lisocabtagene Maraleucel (liso-cel) in relapsed or refractory (R\/R) large B-cell lymphomas (LBCL)","volume":"138","author":"Abramson","year":"2021","journal-title":"Blood."},{"issue":"16_suppl","key":"10.1016\/j.blre.2023.101140_bb0425","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2022.40.16_suppl.7548","volume":"40","author":"Westin","year":"2022","journal-title":"J Clin Oncol"},{"issue":"14","key":"10.1016\/j.blre.2023.101140_bb0430","doi-asserted-by":"crossref","DOI":"10.1182\/blood.2022018730","article-title":"Lisocabtagene maraleucel as second-line therapy for large B-cell lymphoma: primary analysis of the phase 3 TRANSFORM study","volume":"141","author":"Abramson","year":"2023","journal-title":"Blood."},{"issue":"3","key":"10.1016\/j.blre.2023.101140_bb0435","doi-asserted-by":"crossref","DOI":"10.1111\/bjh.17738","article-title":"The impact of bridging therapy prior to CD19-directed chimeric antigen receptor T-cell therapy in patients with large B-cell lymphoma","volume":"195","author":"Lutfi","year":"2021","journal-title":"Br J Haematol"},{"issue":"1","key":"10.1016\/j.blre.2023.101140_bb0440","doi-asserted-by":"crossref","DOI":"10.1097\/CJI.0000000000000284","article-title":"Radiation priming chimeric antigen receptor T-cell therapy in relapsed\/refractory diffuse large B-cell lymphoma with high tumor burden","volume":"43","author":"Qu","year":"2020","journal-title":"J Immunother"},{"issue":"5","key":"10.1016\/j.blre.2023.101140_bb0445","doi-asserted-by":"crossref","DOI":"10.1002\/hon.3001","article-title":"Comparing apples and oranges: the ZUMA-7, TRANSFORM and BELINDA trials","volume":"40","author":"Bommier","year":"2022","journal-title":"Hematol Oncol"},{"issue":"8","key":"10.1016\/j.blre.2023.101140_bb0450","doi-asserted-by":"crossref","DOI":"10.1016\/S1470-2045(22)00339-4","article-title":"Lisocabtagene maraleucel as second-line therapy in adults with relapsed or refractory large B-cell lymphoma who were not intended for haematopoietic stem cell transplantation (PILOT): an open-label, phase 2 study","volume":"23","author":"Sehgal","year":"2022","journal-title":"Lancet Oncol"},{"issue":"7","key":"10.1016\/j.blre.2023.101140_bb0455","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMc2030164","article-title":"Five-year outcomes for refractory B-cell lymphomas with CAR T-cell therapy","volume":"384","author":"Chong","year":"2021","journal-title":"N Engl J Med"},{"issue":"Supplement 1","key":"10.1016\/j.blre.2023.101140_bb0460","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1182\/blood-2020-137045","article-title":"Myc expression and tumor-infiltrating T cells are associated with response in patients (pts) with relapsed\/refractory diffuse large B-cell lymphoma (r\/r DLBCL) treated with Tisagenlecleucel in the Juliet trial","volume":"136","author":"Jaeger","year":"2020","journal-title":"Blood."},{"issue":"12","key":"10.1016\/j.blre.2023.101140_bb0465","doi-asserted-by":"crossref","DOI":"10.1158\/2159-8290.CD-15-1020","article-title":"Convergence of acquired mutations and alternative splicing of CD19 enables resistance to CART-19 immunotherapy","volume":"5","author":"Sotillo","year":"2015","journal-title":"Cancer Discov"},{"issue":"7","key":"10.1016\/j.blre.2023.101140_bb0470","doi-asserted-by":"crossref","DOI":"10.3390\/cancers12071760","article-title":"MHC class I downregulation in cancer: underlying mechanisms and potential targets for cancer immunotherapy","volume":"12","author":"Cornel","year":"2020","journal-title":"Cancers."},{"issue":"1","key":"10.1016\/j.blre.2023.101140_bb0475","doi-asserted-by":"crossref","DOI":"10.1080\/14712598.2022.2154601","article-title":"CAR-NK cells: a promising cellular immunotherapy in lymphoma","volume":"23","author":"Khanmohammadi","year":"2023","journal-title":"Expert Opin Biol Ther"},{"key":"10.1016\/j.blre.2023.101140_bb0480","first-page":"11","article-title":"From CAR-T cells to CAR-NK cells: a developing immunotherapy method for Hematological malignancies","author":"Lu","year":"2021","journal-title":"Front Oncol"},{"issue":"2","key":"10.1016\/j.blre.2023.101140_bb0485","doi-asserted-by":"crossref","DOI":"10.1038\/emm.2014.114","article-title":"Understanding of molecular mechanisms in natural killer cell therapy","volume":"47","author":"Yoon","year":"2015","journal-title":"Exp Mol Med"},{"issue":"2","key":"10.1016\/j.blre.2023.101140_bb0490","doi-asserted-by":"crossref","DOI":"10.1111\/bjh.17186","article-title":"Chimeric antigen receptor (CAR) natural killer (NK)-cell therapy: leveraging the power of innate immunity","volume":"193","author":"Rafei","year":"2021","journal-title":"Br J Haematol"},{"issue":"4","key":"10.1016\/j.blre.2023.101140_bb0495","doi-asserted-by":"crossref","DOI":"10.1016\/j.bbmt.2015.12.028","article-title":"Phase II study of Haploidentical natural killer cell infusion for treatment of relapsed or persistent myeloid malignancies following allogeneic hematopoietic cell transplantation","volume":"22","author":"Shaffer","year":"2016","journal-title":"Biol Blood Marrow Transplant"},{"issue":"21","key":"10.1016\/j.blre.2023.101140_bb0500","doi-asserted-by":"crossref","DOI":"10.1182\/blood-2009-05-222190","article-title":"NK cells mediate reduction of GVHD by inhibiting activated, alloreactive T cells while retaining GVT effects","volume":"115","author":"Olson","year":"2010","journal-title":"Blood."},{"issue":"11","key":"10.1016\/j.blre.2023.101140_bb0505","doi-asserted-by":"crossref","DOI":"10.1038\/sj.leu.2403524","article-title":"Purified donor NK-lymphocyte infusion to consolidate engraftment after haploidentical stem cell transplantation","volume":"18","author":"Passweg","year":"2004","journal-title":"Leukemia."},{"issue":"6","key":"10.1016\/j.blre.2023.101140_bb0510","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa1910607","article-title":"Use of CAR-transduced natural killer cells in CD19-positive lymphoid Tumors","volume":"382","author":"Liu","year":"2020","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.blre.2023.101140_bb0515","doi-asserted-by":"crossref","DOI":"10.1016\/j.stem.2018.06.002","article-title":"Human iPSC-derived natural killer cells engineered with chimeric antigen receptors enhance anti-tumor activity","volume":"23","author":"Li","year":"2018","journal-title":"Cell Stem Cell"},{"issue":"Supplement 1","key":"10.1016\/j.blre.2023.101140_bb0520","doi-asserted-by":"crossref","DOI":"10.1182\/blood-2020-142419","article-title":"Results of a phase 1 trial of Gda-201, nicotinamide-expanded allogeneic natural killer (NK) cells in patients with refractory non-Hodgkin lymphoma (NHL) and multiple myeloma","volume":"136","author":"Bachanova","year":"2020","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.blre.2023.101140_bb0525","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa1709866","article-title":"Tisagenlecleucel in children and young adults with B-cell lymphoblastic Leukemia","volume":"378","author":"Maude","year":"2018","journal-title":"N Engl J Med"},{"issue":"12","key":"10.1016\/j.blre.2023.101140_bb0530","doi-asserted-by":"crossref","DOI":"10.1182\/blood.2021010930","article-title":"CD19 target evasion as a mechanism of relapse in large B-cell lymphoma treated with axicabtagene ciloleucel","volume":"138","author":"Plaks","year":"2021","journal-title":"Blood."},{"issue":"5","key":"10.1016\/j.blre.2023.101140_bb0535","doi-asserted-by":"crossref","DOI":"10.3324\/haematol.2017.183459","article-title":"Sequential loss of tumor surface antigens following chimeric antigen receptor T-cell therapies in diffuse large B-cell lymphoma","volume":"103","author":"Shalabi","year":"2018","journal-title":"Haematologica."},{"key":"10.1016\/j.blre.2023.101140_bb0540","first-page":"13","article-title":"Custom CARs: leveraging the adaptability of allogeneic CAR therapies to address current challenges in relapsed\/refractory DLBCL","author":"Jeyakumar","year":"2022","journal-title":"Front Immunol"},{"issue":"10","key":"10.1016\/j.blre.2023.101140_bb0545","doi-asserted-by":"crossref","DOI":"10.1038\/s41591-020-1081-3","article-title":"Bispecific anti-CD20, anti-CD19 CAR T cells for relapsed B cell malignancies: a phase 1 dose escalation and expansion trial","volume":"26","author":"Shah","year":"2020","journal-title":"Nat Med"},{"issue":"Supplement 1","key":"10.1016\/j.blre.2023.101140_bb0550","doi-asserted-by":"crossref","DOI":"10.1182\/blood-2020-143239","article-title":"CD19\/CD22 dual-targeted chimeric antigen receptor T-cell therapy for relapsed\/refractory aggressive B-cell lymphoma: a safety and efficacy study","volume":"136","author":"Hu","year":"2020","journal-title":"Blood."},{"issue":"Supplement 1","key":"10.1016\/j.blre.2023.101140_bb0555","doi-asserted-by":"crossref","DOI":"10.1182\/blood-2018-99-113714","article-title":"CAR22\/19 cocktail therapy for patients with refractory\/relapsed B-cell malignancies","volume":"132","author":"Huang","year":"2018","journal-title":"Blood."},{"issue":"8","key":"10.1016\/j.blre.2023.101140_bb0560","doi-asserted-by":"crossref","DOI":"10.1038\/s41591-021-01436-0","article-title":"CAR T cells with dual targeting of CD19 and CD22 in adult patients with recurrent or refractory B cell malignancies: a phase 1 trial","volume":"27","author":"Spiegel","year":"2021","journal-title":"Nat Med"},{"issue":"14","key":"10.1016\/j.blre.2023.101140_bb0565","article-title":"Optimized tandem CD19\/CD20 CAR-engineered T cells in refractory\/relapsed B-cell lymphoma","volume":"136","author":"Tong","year":"2020","journal-title":"Blood."},{"issue":"1","key":"10.1016\/j.blre.2023.101140_bb0570","doi-asserted-by":"crossref","DOI":"10.1182\/blood.2019000017","article-title":"Efficacy and safety of CAR19\/22 T-cell cocktail therapy in patients with refractory\/relapsed B-cell malignancies","volume":"135","author":"Wang","year":"2020","journal-title":"Blood."},{"issue":"9","key":"10.1016\/j.blre.2023.101140_bb0575","doi-asserted-by":"crossref","DOI":"10.1158\/2326-6066.CIR-20-0675","article-title":"CD19\/CD22 dual-targeted car t-cell therapy for relapsed\/refractory aggressive b-cell lymphoma: a safety and efficacy study","volume":"9","author":"Wei","year":"2021","journal-title":"Cancer Immunol Res"},{"key":"10.1016\/j.blre.2023.101140_bb0580","first-page":"11","article-title":"A prospective investigation of bispecific CD19\/22 CAR T cell therapy in patients with relapsed or refractory B cell non-Hodgkin lymphoma","author":"Zhang","year":"2021","journal-title":"Front Oncol"},{"issue":"1","key":"10.1016\/j.blre.2023.101140_bb0585","doi-asserted-by":"crossref","DOI":"10.1038\/s41375-021-01345-8","article-title":"Long-term activity of tandem CD19\/CD20 CAR therapy in refractory\/relapsed B-cell lymphoma: a single-arm, phase 1\u20132 trial","volume":"36","author":"Zhang","year":"2022","journal-title":"Leukemia."},{"issue":"JUL","key":"10.1016\/j.blre.2023.101140_bb0590","article-title":"Invariant natural killer T cells as suppressors of graft-versus-host disease in allogeneic hematopoietic stem cell transplantation","volume":"8","author":"Mavers","year":"2017","journal-title":"Front Immunol"},{"issue":"4","key":"10.1016\/j.blre.2023.101140_bb0595","doi-asserted-by":"crossref","DOI":"10.1016\/j.ccell.2018.08.017","article-title":"Enhanced anti-lymphoma activity of CAR19-iNKT cells underpinned by dual CD19 and CD1d targeting","volume":"34","author":"Rotolo","year":"2018","journal-title":"Cancer Cell"},{"issue":"21","key":"10.1016\/j.blre.2023.101140_bb0600","doi-asserted-by":"crossref","DOI":"10.1158\/1078-0432.CCR-21-1329","article-title":"Allogeneic CAR invariant natural killer T cells exert potent antitumor effects through host CD8 T-cell cross-priming","volume":"27","author":"Simonetta","year":"2021","journal-title":"Clin Cancer Res"},{"issue":"7","key":"10.1016\/j.blre.2023.101140_bb0605","doi-asserted-by":"crossref","DOI":"10.1038\/nri2781","article-title":"\u03b3 \u03b4 T cell effector functions: a blend of innate programming and acquired plasticity","volume":"10","author":"Bonneville","year":"2010","journal-title":"Nat Rev Immunol"},{"issue":"2","key":"10.1016\/j.blre.2023.101140_bb0610","doi-asserted-by":"crossref","DOI":"10.1002\/cti2.1373","article-title":"Allogeneic CD20-targeted \u03b3\u03b4 T cells exhibit innate and adaptive antitumor activities in preclinical B-cell lymphoma models","volume":"11","author":"Nishimoto","year":"2022","journal-title":"Clin Transl Immunol"},{"key":"10.1016\/j.blre.2023.101140_bb0615","first-page":"11","article-title":"Gamma-Delta CAR-T cells show CAR-directed and independent activity against Leukemia","author":"Rozenbaum","year":"2020","journal-title":"Front Immunol"},{"issue":"24","key":"10.1016\/j.blre.2023.101140_bb0620","doi-asserted-by":"crossref","DOI":"10.1182\/bloodadvances.2020003036","article-title":"CAR T cells or allogeneic transplantation as standard of care for advanced large B-cell lymphoma: an intent-to-treat comparison","volume":"4","author":"Dreger","year":"2020","journal-title":"Blood Adv"},{"issue":"2","key":"10.1016\/j.blre.2023.101140_bb0625","doi-asserted-by":"crossref","DOI":"10.1111\/bjh.14046","article-title":"Allogeneic transplantation provides durable remission in a subset of DLBCL patients relapsing after autologous transplantation","volume":"174","author":"Fenske","year":"2016","journal-title":"Br J Haematol"},{"issue":"2","key":"10.1016\/j.blre.2023.101140_bb0630","doi-asserted-by":"crossref","DOI":"10.1182\/bloodadvances.2021005788","article-title":"Allogeneic transplant and CAR-T therapy after autologous transplant failure in DLBCL: a noncomparative cohort analysis","volume":"6","author":"Hamadani","year":"2022","journal-title":"Blood Adv"},{"issue":"20","key":"10.1016\/j.blre.2023.101140_bb0635","doi-asserted-by":"crossref","DOI":"10.1182\/bloodadvances.2019000593","article-title":"Safety of allogeneic hematopoietic cell transplant in adults after CD19-targeted CAR T-cell therapy","volume":"3","author":"Shadman","year":"2019","journal-title":"Blood Adv"},{"issue":"5","key":"10.1016\/j.blre.2023.101140_bb0640","doi-asserted-by":"crossref","DOI":"10.1093\/annonc\/mdy056","article-title":"Phase IIa study of the CD19 antibody MOR208 in patients with relapsed or refractory B-cell non- Hodgkin\u2019s lymphoma","volume":"29","author":"Jurczak","year":"2018","journal-title":"Ann Oncol"},{"issue":"24","key":"10.1016\/j.blre.2023.101140_bb0645","doi-asserted-by":"crossref","DOI":"10.1182\/blood-2014-08-593269","article-title":"A phase 1 trial of the fc-engineered CD19 antibody XmAb5574 (MOR00208) demonstrates safety and preliminary efficacy in relapsed CLL","volume":"124","author":"Woyach","year":"2014","journal-title":"Blood."},{"issue":"6","key":"10.1016\/j.blre.2023.101140_bb0650","doi-asserted-by":"crossref","DOI":"10.1182\/blood-2009-06-229039","article-title":"CD19 targeting of chronic lymphocytic leukemia with a novel fc-domain-engineered monoclonal antibody","volume":"115","author":"Awan","year":"2010","journal-title":"Blood."},{"issue":"25","key":"10.1016\/j.blre.2023.101140_bb0655","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2014.59.5363","article-title":"Mechanisms of action of lenalidomide in B-cell non-hodgkin lymphoma","volume":"33","author":"Gribben","year":"2015","journal-title":"J Clin Oncol"},{"issue":"19","key":"10.1016\/j.blre.2023.101140_bb0660","doi-asserted-by":"crossref","DOI":"10.1158\/0008-5472.CAN-08-2268","article-title":"Potent in vitro and in vivo activity of an fc-engineered anti-CD19 monoclonal antibody against lymphoma and leukemia","volume":"68","author":"Horton","year":"2008","journal-title":"Cancer Res"},{"issue":"7","key":"10.1016\/j.blre.2023.101140_bb0665","doi-asserted-by":"crossref","DOI":"10.1016\/S1470-2045(20)30225-4","article-title":"Tafasitamab plus lenalidomide in relapsed or refractory diffuse large B-cell lymphoma (L-MIND): a multicentre, prospective, single-arm, phase 2 study","volume":"21","author":"Salles","year":"2020","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.blre.2023.101140_bb0670","doi-asserted-by":"crossref","DOI":"10.3324\/haematol.2020.275958","article-title":"Long-term outcomes from the phase II L-MIND study of tafasitamab (MOR208) plus lenalidomide in patients with relapsed or refractory diffuse large B-cell lymphoma","author":"Duell","year":"2021","journal-title":"Haematologica"},{"issue":"23","key":"10.1016\/j.blre.2023.101140_bb0675","doi-asserted-by":"crossref","DOI":"10.1158\/1078-0432.CCR-19-0711","article-title":"A phase I study of ADCT-402 (loncastuximab tesirine), a novel pyrrolobenzodiazepine-based antibody\u2013drug conjugate, in relapsed\/ refractory B-cell non-Hodgkin lymphoma","volume":"25","author":"Kahl","year":"2019","journal-title":"Clin Cancer Res"},{"issue":"6","key":"10.1016\/j.blre.2023.101140_bb0680","doi-asserted-by":"crossref","DOI":"10.1016\/S1470-2045(21)00139-X","article-title":"Loncastuximab tesirine in relapsed or refractory diffuse large B-cell lymphoma (LOTIS-2): a multicentre, open-label, single-arm, phase 2 trial","volume":"22","author":"Caimi","year":"2021","journal-title":"Lancet Oncol"},{"issue":"6","key":"10.1016\/j.blre.2023.101140_bb0685","doi-asserted-by":"crossref","DOI":"10.1016\/S1470-2045(15)70128-2","article-title":"Safety and activity of the anti-CD79B antibody-drug conjugate polatuzumab vedotin in relapsed or refractory B-cell non-Hodgkin lymphoma and chronic lymphocytic leukaemia: a phase 1 study","volume":"16","author":"Palanca-Wessels","year":"2015","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.blre.2023.101140_bb0690","series-title":"Polatuzumab vedotin in relapsed or refractory diffuse large B-cell lymphoma","volume":"38","author":"Sehn","year":"2020"},{"issue":"5","key":"10.1016\/j.blre.2023.101140_bb0695","doi-asserted-by":"crossref","DOI":"10.1111\/bjh.13085","article-title":"CD30 expression in de novo diffuse large B-cell lymphoma: a population-based study from British Columbia","volume":"167","author":"Slack","year":"2014","journal-title":"Br J Haematol"},{"issue":"11","key":"10.1016\/j.blre.2023.101140_bb0700","doi-asserted-by":"crossref","DOI":"10.3109\/10428194.2013.778407","article-title":"Frequency and extent of CD30 expression in diffuse large B-cell lymphoma and its relation to clinical and biologic factors: a retrospective study of 167 cases","volume":"54","author":"Campuzano-Zuluaga","year":"2013","journal-title":"Leuk Lymphoma"},{"issue":"14","key":"10.1016\/j.blre.2023.101140_bb0705","doi-asserted-by":"crossref","DOI":"10.1182\/blood-2012-10-461848","article-title":"CD30 expression defines a novel subgroup of diffuse large B-cell lymphoma with favorable prognosis and distinct gene expression signature: a report from the international DLBCL rituximab-CHOP consortium program study","volume":"121","author":"Hu","year":"2013","journal-title":"Blood."},{"issue":"9","key":"10.1016\/j.blre.2023.101140_bb0710","doi-asserted-by":"crossref","DOI":"10.1182\/blood-2014-09-598763","article-title":"Brentuximab vedotin demonstrates objective responses in a phase 2 study of relapsed\/refractory DLBCL with variable CD30 expression","volume":"125","author":"Jacobsen","year":"2015","journal-title":"Blood."},{"key":"10.1016\/j.blre.2023.101140_bb0715","first-page":"13","article-title":"Role of bispecific antibodies in relapsed\/refractory diffuse large B-cell lymphoma in the CART era","author":"Gonz\u00e1lez","year":"2022","journal-title":"Front Immunol"},{"key":"10.1016\/j.blre.2023.101140_bb0720","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1158\/1078-0432.CCR-15-0612","article-title":"FDA approval: Blinatumomab","volume":"21","author":"Przepiorka","year":"2015","journal-title":"Clin Cancer Res"},{"issue":"11","key":"10.1016\/j.blre.2023.101140_bb0725","doi-asserted-by":"crossref","DOI":"10.1182\/blood-2015-06-651380","article-title":"Phase 2 study of the bispecific T-cell engager (bite) antibody Blinatumomab in relapsed\/refractory diffuse large B-cell lymphoma","volume":"127","author":"Viardot","year":"2016","journal-title":"Blood."},{"issue":"Supplement 1","key":"10.1016\/j.blre.2023.101140_bb0730","doi-asserted-by":"crossref","DOI":"10.1182\/blood-2020-136659","article-title":"Odronextamab (REGN1979), a human CD20 x CD3 bispecific antibody, induces durable, complete responses in patients with highly refractory B-cell non-hodgkin lymphoma, including patients refractory to CAR T therapy","volume":"136","author":"Bannerji","year":"2020","journal-title":"Blood"},{"issue":"Supplement 1","key":"10.1016\/j.blre.2023.101140_bb0735","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1182\/blood-2020-136044","article-title":"Glofitamab step-up dosing induces high response rates in patients with hard-to-treat refractory or relapsed non-Hodgkin lymphoma","volume":"136","author":"Hutchings","year":"2020","journal-title":"Blood."},{"issue":"18","key":"10.1016\/j.blre.2023.101140_bb0740","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.20.03175","article-title":"Glofitamab, a novel, bivalent CD20-targeting t-cell-engaging bispecific antibody, induces durable complete remissions in relapsed or refractory B-cell lymphoma: a phase i trial","volume":"39","author":"Hutchings","year":"2021","journal-title":"J Clin Oncol"},{"issue":"Supplement 1","key":"10.1016\/j.blre.2023.101140_bb0745","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1182\/blood-2020-133820","article-title":"Subcutaneous Epcoritamab induces complete responses with an encouraging safety profile across relapsed\/refractory B-cell non-Hodgkin lymphoma subtypes, including patients with prior CAR-T therapy: updated dose escalation data","volume":"136","author":"Hutchings","year":"2020","journal-title":"Blood."},{"issue":"Supplement_1","key":"10.1016\/j.blre.2023.101140_bb0750","doi-asserted-by":"crossref","DOI":"10.1182\/blood-2019-123742","article-title":"Mosunetuzumab induces complete remissions in poor prognosis non-Hodgkin lymphoma patients, including those who are resistant to or relapsing after chimeric antigen receptor T-cell (CAR-T) therapies, and is active in treatment through multiple lines","volume":"134","author":"Schuster","year":"2019","journal-title":"Blood."},{"issue":"9","key":"10.1016\/j.blre.2023.101140_bb0755","doi-asserted-by":"crossref","DOI":"10.1080\/10428194.2020.1759055","article-title":"Open-label, phase 2 study of blinatumomab as second salvage therapy in adults with relapsed\/refractory aggressive B-cell non-Hodgkin lymphoma","volume":"61","author":"Coyle","year":"2020","journal-title":"Leuk Lymphoma"},{"issue":"24","key":"10.1016\/j.blre.2023.101140_bb0760","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa2206913","article-title":"Glofitamab for relapsed or refractory diffuse large B-cell lymphoma","volume":"387","author":"Dickinson","year":"2022","journal-title":"N Engl J Med"},{"issue":"10306","key":"10.1016\/j.blre.2023.101140_bb0765","doi-asserted-by":"crossref","DOI":"10.1016\/S0140-6736(21)00889-8","article-title":"Dose escalation of subcutaneous epcoritamab in patients with relapsed or refractory B-cell non-Hodgkin lymphoma: an open-label, phase 1\/2 study","volume":"398","author":"Hutchings","year":"2021","journal-title":"Lancet"},{"issue":"12","key":"10.1016\/j.blre.2023.101140_bb0770","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.22.01725","article-title":"Epcoritamab, a novel, subcutaneous CD3xCD20 bispecific T-cell-engaging antibody, in relapsed or refractory large B-cell lymphoma: dose expansion in a phase I\/II trial","volume":"41","author":"Thieblemont","year":"2023","journal-title":"J Clin Oncol"},{"issue":"5","key":"10.1016\/j.blre.2023.101140_bb0775","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.21.00931","article-title":"Single-agent Mosunetuzumab shows durable complete responses in patients with relapsed or refractory B-cell lymphomas: phase I dose-escalation study","volume":"40","author":"Budde","year":"2022","journal-title":"J Clin Oncol"},{"issue":"5","key":"10.1016\/j.blre.2023.101140_bb0780","doi-asserted-by":"crossref","DOI":"10.1016\/S2352-3026(22)00072-2","article-title":"Odronextamab, a human CD20\u00d7CD3 bispecific antibody in patients with CD20-positive B-cell malignancies (ELM-1): results from the relapsed or refractory non-Hodgkin lymphoma cohort in a single-arm, multicentre, phase 1 trial","volume":"9","author":"Bannerji","year":"2022","journal-title":"Lancet Haematol"},{"issue":"Supplement 1","key":"10.1016\/j.blre.2023.101140_bb0785","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1182\/blood-2020-136295","article-title":"Mosunetuzumab, a novel CD20\/CD3 bispecific antibody, in combination with CHOP confers high response rates in patients with diffuse large B-cell lymphoma","volume":"136","author":"Phillips","year":"2020","journal-title":"Blood."},{"key":"10.1016\/j.blre.2023.101140_bb0790","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1182\/blood-2021-146569","article-title":"Subcutaneous Epcoritamab in combination with R-CHOP in patients with previously untreated high-risk diffuse large B-cell lymphoma: preliminary results from a phase 1\/2 trial","volume":"138","author":"Belada","year":"2021","journal-title":"Blood."},{"issue":"1","key":"10.1016\/j.blre.2023.101140_bb0795","doi-asserted-by":"crossref","DOI":"10.1186\/s13045-017-0550-8","article-title":"A phase I study of selinexor in combination with high-dose cytarabine and mitoxantrone for remission induction in patients with acute myeloid leukemia","volume":"11","author":"Wang","year":"2018","journal-title":"J Hematol Oncol"},{"issue":"7","key":"10.1016\/j.blre.2023.101140_bb0800","doi-asserted-by":"crossref","DOI":"10.1016\/S2352-3026(20)30120-4","article-title":"Selinexor in patients with relapsed or refractory diffuse large B-cell lymphoma (SADAL): a single-arm, multinational, multicentre, open-label, phase 2 trial","volume":"7","author":"Kalakonda","year":"2020","journal-title":"Lancet Haematol"},{"issue":"10","key":"10.1016\/j.blre.2023.101140_bb0805","doi-asserted-by":"crossref","first-page":"1416","DOI":"10.1182\/blood.2020007939","article-title":"Is autologous transplant in relapsed DLBCL patients achieving only a PET+ PR appropriate in the CAR T-cell era?","volume":"137","author":"Shah","year":"2021","journal-title":"Blood."},{"issue":"9","key":"10.1016\/j.blre.2023.101140_bb0810","doi-asserted-by":"crossref","first-page":"1330","DOI":"10.1182\/blood.2021013289","article-title":"Autologous transplant vs chimeric antigen receptor T-cell therapy for relapsed DLBCL in partial remission","volume":"139","author":"Shadman","year":"2022","journal-title":"Blood."},{"issue":"11","key":"10.1016\/j.blre.2023.101140_bb0815","doi-asserted-by":"crossref","first-page":"2733","DOI":"10.1007\/s00277-021-04650-5","article-title":"The role of autologous stem cell transplantation (ASCT) in aggressive B-cell lymphomas: real-world data from a retrospective single-center analysis","volume":"100","author":"Wullenkord","year":"2021","journal-title":"Ann Hematol"},{"issue":"10","key":"10.1016\/j.blre.2023.101140_bb0820","doi-asserted-by":"crossref","first-page":"2279","DOI":"10.1002\/cncr.32752","article-title":"Outcomes of rituximab-BEAM versus BEAM conditioning regimen in patients with diffuse large B cell lymphoma undergoing autologous transplantation","volume":"126","author":"Jagadeesh","year":"2020","journal-title":"Cancer."},{"issue":"15_suppl","key":"10.1016\/j.blre.2023.101140_bb0825","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2018.36.15_suppl.e19502","article-title":"Real world survival rates and healthcare utilization among SEER-Medicare patients treated with hematopoietic stem cell transplant (HSCT) for relapsed\/refractory diffuse large b-cell lymphoma (RR-DLBCL)","volume":"36","author":"Purdum","year":"2018","journal-title":"J Clin Oncol"},{"issue":"15_suppl","key":"10.1016\/j.blre.2023.101140_bb0830","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2018.36.15_suppl.7545","article-title":"Overall survival (OS) and transplantation (ASCT) utilization in real-world patients with relapsed\/refractory diffuse large B-cell lymphoma (RR-DLBCL)","volume":"36","author":"Nabhan","year":"2018","journal-title":"J Clin Oncol"},{"issue":"3","key":"10.1016\/j.blre.2023.101140_bb0835","article-title":"An international survey on the management of patients receiving CAR T-cell therapy for haematological malignancies on behalf of the chronic malignancies working party of EBMT","volume":"67","author":"Hayden","year":"2019","journal-title":"Curr Res Transl Med"},{"issue":"5","key":"10.1016\/j.blre.2023.101140_bb0840","doi-asserted-by":"crossref","DOI":"10.1634\/theoncologist.2015-0421","article-title":"Chimeric antigen receptor T-cell therapy for the community oncologist","volume":"21","author":"Maus","year":"2016","journal-title":"Oncologist"},{"issue":"Supplement 1","key":"10.1016\/j.blre.2023.101140_bb0845","article-title":"Recent bendamustine treatment before apheresis has a negative impact on outcomes in patients with large B-cell lymphoma receiving chimeric antigen receptor T-cell therapy","volume":"140","author":"Iacoboni","year":"2022","journal-title":"Blood."},{"issue":"Supplement 1","key":"10.1016\/j.blre.2023.101140_bb0850","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1182\/blood-2022-167620","article-title":"Tafasitamab and lenalidomide in relapsed\/refractory large B cell lymphoma (R\/R LBCL): real world outcomes in a multicenter retrospective study","volume":"140","author":"Qualls","year":"2022","journal-title":"Blood."},{"issue":"Supplement 1","key":"10.1016\/j.blre.2023.101140_bb0855","doi-asserted-by":"crossref","first-page":"8058","DOI":"10.1182\/blood-2022-167753","article-title":"Real-world outcomes in relapsed\/refractory DLBCL patients who received polatuzumab vedotin PLUS bendamustine and rituximab or tafasitamab plus lenalidomide by line of therapy","volume":"140","author":"Hamadani","year":"2022","journal-title":"Blood."},{"issue":"3","key":"10.1016\/j.blre.2023.101140_bb0860","doi-asserted-by":"crossref","DOI":"10.1016\/j.clml.2020.12.013","article-title":"Polatuzumab vedotin for relapsed\/refractory aggressive B-cell lymphoma: a multicenter post-marketing analysis","volume":"21","author":"Smith","year":"2021","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"26","key":"10.1016\/j.blre.2023.101140_bb0865","doi-asserted-by":"crossref","first-page":"2531","DOI":"10.1056\/NEJMoa1707447","article-title":"Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma","volume":"377","author":"Neelapu","year":"2017","journal-title":"N Engl J Med"},{"issue":"7","key":"10.1016\/j.blre.2023.101140_bb0870","doi-asserted-by":"crossref","first-page":"1432","DOI":"10.1182\/bloodadvances.2019001304","article-title":"Grading and management of cytokine release syndrome in patients treated with tisagenlecleucel in the JULIET trial","volume":"4","author":"Schuster","year":"2020","journal-title":"Blood Adv"},{"issue":"3","key":"10.1016\/j.blre.2023.101140_bb0875","doi-asserted-by":"crossref","first-page":"150","DOI":"10.36401\/JIPO-21-2","article-title":"Real-world experiences of CAR T-cell therapy for large B-cell lymphoma: how similar are they to the prospective studies?","volume":"4","author":"Tang","year":"2021","journal-title":"J Immunother Precis Oncol"},{"issue":"10","key":"10.1016\/j.blre.2023.101140_bb0880","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1016\/j.jtct.2022.07.011","article-title":"Patterns of use, outcomes, and resource utilization among recipients of commercial axicabtagene ciloleucel and tisagenlecleucel for relapsed\/refractory aggressive B cell lymphomas","volume":"28","author":"Riedell","year":"2022","journal-title":"Transplant Cell Ther"},{"issue":"10","key":"10.1016\/j.blre.2023.101140_bb0885","doi-asserted-by":"crossref","DOI":"10.1002\/cam4.3881","article-title":"Real-world evidence of tisagenlecleucel for the treatment of relapsed or refractory large B-cell lymphoma","volume":"10","author":"Iacoboni","year":"2021","journal-title":"Cancer Med"},{"issue":"Supplement_1","key":"10.1016\/j.blre.2023.101140_bb0890","doi-asserted-by":"crossref","DOI":"10.1182\/blood-2019-125286","article-title":"The real life accessibility to CAR T-cell therapy: current experience in the only active Center in Italy","volume":"134","author":"Guidetti","year":"2019","journal-title":"Blood."},{"issue":"Supplement_1","key":"10.1016\/j.blre.2023.101140_bb0895","volume":"134","author":"Jain","year":"2019","journal-title":"Blood."},{"issue":"Supplement_1","key":"10.1016\/j.blre.2023.101140_bb0900","doi-asserted-by":"crossref","DOI":"10.1182\/blood-2019-124177","article-title":"Real-world data of high-grade lymphoma patients treated with CD19 CAR-T in England","volume":"134","author":"Kuhnl","year":"2019","journal-title":"Blood."},{"issue":"13","key":"10.1016\/j.blre.2023.101140_bb0905","doi-asserted-by":"crossref","DOI":"10.1182\/bloodadvances.2020001837","article-title":"Bridging therapy prior to axicabtagene ciloleucel for relapsed\/refractory large B-cell lymphoma","volume":"4","author":"Pinnix","year":"2020","journal-title":"Blood Adv"},{"key":"10.1016\/j.blre.2023.101140_bb0910","series-title":"Polatuzumab vedotin as a salvage and bridging treatment in relapsed or refractory large B-cell lymphomas","volume":"5","author":"Liebers","year":"2021"},{"issue":"3","key":"10.1016\/j.blre.2023.101140_bb0915","doi-asserted-by":"crossref","DOI":"10.1080\/10428194.2021.1992622","article-title":"CD19 epitope masking by tafasitamab leads to delays in subsequent use of CD19 CAR T-cell therapy in two patients with aggressive mature B-cell lymphomas","volume":"63","author":"Fitzgerald","year":"2022","journal-title":"Leuk Lymphoma"},{"issue":"13","key":"10.1016\/j.blre.2023.101140_bb0920","article-title":"Outcomes of patients with large B-cell lymphoma progressing after axicabtagene ciloleucel therapy","volume":"137","author":"Spiegel","year":"2021","journal-title":"Blood."},{"issue":"2","key":"10.1016\/j.blre.2023.101140_bb0925","doi-asserted-by":"crossref","DOI":"10.1080\/10428194.2021.1986219","article-title":"CD19 expression is maintained in DLBCL patients after treatment with tafasitamab plus lenalidomide in the L-MIND study","volume":"63","author":"Duell","year":"2022","journal-title":"Leuk Lymphoma"},{"issue":"5","key":"10.1016\/j.blre.2023.101140_bb0930","doi-asserted-by":"crossref","DOI":"10.1111\/bjh.18333","article-title":"Sequential loss of B-cell target antigens in multiply relapsed high-grade B-cell lymphoma treated with targeted therapies","volume":"198","author":"Mian","year":"2022","journal-title":"Br J Haematol"},{"issue":"16","key":"10.1016\/j.blre.2023.101140_bb0935","doi-asserted-by":"crossref","DOI":"10.1182\/bloodadvances.2020002587","article-title":"CD19 antibody-drug conjugate therapy in DLBCL does not preclude subsequent responses to CD19-directed CAR T-cell therapy","volume":"4","author":"Thapa","year":"2020","journal-title":"Blood Adv"},{"issue":"5","key":"10.1016\/j.blre.2023.101140_bb0940","doi-asserted-by":"crossref","DOI":"10.1016\/j.clml.2021.11.005","article-title":"The AntiCD19 antibody drug Immunoconjugate Loncastuximab achieves responses in DLBCL relapsing after AntiCD19 CAR-T cell therapy","volume":"22","author":"Caimi","year":"2022","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"Supplement 1","key":"10.1016\/j.blre.2023.101140_bb0945","doi-asserted-by":"crossref","first-page":"9548","DOI":"10.1182\/blood-2022-159626","article-title":"CD19 expression by IHC alone is not a predictor of response to Loncastuximab Tesirine: results from the LOTIS-2 clinical trial and quantitative systems pharmacology Modeling","volume":"140","author":"Caimi","year":"2022","journal-title":"Blood."},{"issue":"Supplement_1","key":"10.1016\/j.blre.2023.101140_bb0950","doi-asserted-by":"crossref","DOI":"10.1182\/blood-2019-128613","article-title":"Expression of CD19 antigen on chronic lymphocytic Leukemia cells after Tafasitamab (anti-CD19) treatment: phase I trial data","volume":"134","author":"Boxhammer","year":"2019","journal-title":"Blood."},{"issue":"Supplement_1","key":"10.1016\/j.blre.2023.101140_bb0955","doi-asserted-by":"crossref","DOI":"10.1182\/blood-2019-130506","article-title":"Targeting of CD19 by Tafasitamab does not impair CD19 directed chimeric antigen receptor T cell activity in vitro","volume":"134","author":"Horvei","year":"2019","journal-title":"Blood."},{"issue":"Supplement 1","key":"10.1016\/j.blre.2023.101140_bb0960","doi-asserted-by":"crossref","DOI":"10.1182\/blood-2021-145649","article-title":"The impact of prior treatment with a CD19 targeting monoclonal antibody on subsequent treatment with CD19 targeting CART cell therapy in preclinical models","volume":"138","author":"Sakemura","year":"2021","journal-title":"Blood."},{"key":"10.1016\/j.blre.2023.101140_bb0965","first-page":"13","article-title":"Best treatment option for patients with refractory aggressive B-cell lymphoma in the CAR-T cell era: real-world evidence from GELTAMO\/GETH Spanish groups","author":"Bastos-Oreiro","year":"2022","journal-title":"Front Immunol"},{"issue":"4","key":"10.1016\/j.blre.2023.101140_bb0970","article-title":"GLA\/DRST real-world outcome analysis of CAR T-cell therapies for large B-cell lymphoma in Germany","volume":"140","author":"Bethge","year":"2022","journal-title":"Blood."},{"issue":"Supplement 1","key":"10.1016\/j.blre.2023.101140_bb0975","doi-asserted-by":"crossref","DOI":"10.1182\/blood-2021-150994","article-title":"Outcome of relapsed\/refractory aggressive B-cell lymphoma patients relapsing after anti-CD19 CAR T-cells and enrolled in the Descar-T French National Registry","volume":"138","author":"Di Blasi","year":"2021","journal-title":"Blood."},{"issue":"8","key":"10.1016\/j.blre.2023.101140_bb0980","doi-asserted-by":"crossref","DOI":"10.1002\/ajh.25505","article-title":"Outcomes of patients with large B-cell lymphomas and progressive disease following CD19-specific CAR T-cell therapy","volume":"94","author":"Chow","year":"2019","journal-title":"Am J Hematol"},{"issue":"24","key":"10.1016\/j.blre.2023.101140_bb0985","doi-asserted-by":"crossref","DOI":"10.1182\/blood.2022016945","article-title":"Outcomes of patients with aggressive B-cell lymphoma after failure of anti-CD19 CAR T-cell therapy: a DESCAR-T analysis","volume":"140","author":"Di Blasi","year":"2022","journal-title":"Blood."},{"issue":"21","key":"10.1016\/j.blre.2023.101140_bb0990","doi-asserted-by":"crossref","DOI":"10.1182\/bloodadvances.2020003092","article-title":"Real-world evidence of tisagenlecleucel for pediatric acute lymphoblastic leukemia and non-Hodgkin lymphoma","volume":"4","author":"Pasquini","year":"2020","journal-title":"Blood Adv"},{"issue":"Supplement 1","key":"10.1016\/j.blre.2023.101140_bb0995","doi-asserted-by":"crossref","DOI":"10.1182\/blood-2021-147568","article-title":"Novel agents may be preferable to chemotherapy for large B-cell lymphoma progressing after CD19-CAR-T: a Multicenter observational study","volume":"138","author":"Alarcon Tomas","year":"2021","journal-title":"Blood."},{"issue":"Supplement 1","key":"10.1016\/j.blre.2023.101140_bb1000","doi-asserted-by":"crossref","DOI":"10.1182\/blood-2021-147433","article-title":"Outcomes and treatment patterns in patients with aggressive B-cell lymphoma after failure of anti-CD19 CAR T-cell therapy","volume":"138","author":"Zurko","year":"2021","journal-title":"Blood."},{"issue":"Supplement 1","key":"10.1016\/j.blre.2023.101140_bb1005","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1182\/blood-2022-169219","article-title":"Salvage treatment with novel agents is preferable to standard chemotherapy in patients with large B-cell lymphoma progressing after chimeric antigen receptor T-cell therapy","volume":"140","author":"Iacoboni","year":"2022","journal-title":"Blood."}],"container-title":["Blood Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0268960X23001017?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0268960X23001017?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T20:29:53Z","timestamp":1759436993000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0268960X23001017"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1]]},"references-count":201,"alternative-id":["S0268960X23001017"],"URL":"https:\/\/doi.org\/10.1016\/j.blre.2023.101140","relation":{},"ISSN":["0268-960X"],"issn-type":[{"value":"0268-960X","type":"print"}],"subject":[],"published":{"date-parts":[[2024,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A paradox of choice: Sequencing therapy in relapsed\/refractory diffuse large B-cell lymphoma","name":"articletitle","label":"Article Title"},{"value":"Blood Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.blre.2023.101140","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"101140"}}